Glatiramer Acetate and Tysabri

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ask your doctor before using natalizumab together with glatiramer. Natalizumab increases the risk of a serious viral infection of the brain that can lead to disability or death. This risk is higher if you have a weak immune system or are receiving certain medications. Call your doctor at once if you develop any signs of infection such as fever, chills, sore throat, cough, stuffy nose, redness, pain, swelling, or painful urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: The use of natalizumab with immunosuppressant, immunomodulating, or antineoplastic agents may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain. In clinical trials, PML occurred in two of 1869 patients with multiple sclerosis treated with natalizumab for a median of 120 weeks and one of 1043 patients with Crohn's disease after eight doses of natalizumab. Both of the MS patients were receiving concomitant interferon beta therapy, and the third patient was immunocompromised due to recent treatment with azathioprine. However, the number of cases is too few and the number of patients treated too small to reliably conclude that the risk of PML is lower with natalizumab monotherapy.

MANAGEMENT: The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been evaluated. Patients receiving such agents should not be treated with natalizumab because of the possibility of increased risk of infections, including PML. However, short courses of corticosteroids may be given. All patients treated with natalizumab should be monitored closely and the drug discontinued immediately at the first sign or symptom suggestive of PML, although it is not known if early detection of PML and discontinuation of natalizumab will mitigate the disease.

Glatiramer Acetate

Generic Name: glatiramer

Brand name: Copaxone, Glatopa

Synonyms: Glatiramer (injection)

What is Glatiramer Acetate?

Tysabri

Generic Name: natalizumab

Brand name: Tysabri

Synonyms: n.a.

What is Tysabri?